Key Takeaways ACAD posted Q3 EPS of $0.26, beating estimates and rising from$0.20 in the prior-year quarter.Revenues climbed 11% year over year to $278.6M, led by Nuplazid and Daybue sales strength.Acadia raised its 2025 outlook for Nuplazid sales, reflecting continued product momentum.Acadia Pharmaceuticals (ACAD) reported third-quarter 2025 earnings of 26 cents per share (excluding a one-time tax benefit), which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had repor ...